Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma. The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combination for lymphoproliferative disorders and identify risk factors for its development. In all, 176 patients treated with fludarabine combination were followed for a median of 41 months (range 6-125 months). In all, 19 cases of t-MDS/AML have been identified for an overall rate of 10.8%. Median overall survival post-t-MDS/AML diagnosis was 11 months. Patients developing t-MDS/AML included 11/54 with follicular lymphoma (FL) (crude rate 20.4%), 5/82 with CLL (6.1%) and 3/24 with Waldenstrom macroglobulinemia or marginal zone lymphoma (12.5%). Most patients had other cytotoxic treatments (median 4, range 0-7) but three with FL had fludarabine combination as their only line of treatment. Of the eleven patients (6.3%) who received mitoxantrone with their first fludarabine combination, four (36.4%) developed t-MDS/AML (P ¼ 0.007). There was a trend toward prior cytotoxic therapy increasing the risk for t-MDS/AML (P ¼ 0.067). Fludarabine combination chemotherapy is associated with a moderate risk of t-MDS/AML particularly when combined with mitoxantrone. This complication should be considered when evaluating the potential benefit of this treatment in lymphoproliferative disorders.
Introduction
Advances in the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL) have resulted in higher response rates and more durable remissions. Chemoimmunotherapy has become the standard of care with the addition of rituximab to combination chemotherapy associated with improved outcomes. 1, 2 As a result, the late toxicities of treatment particularly therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) are becoming a more important concern. It is established that up to 10% of patients with indolent non-Hodgkin lymphoma treated with either standard alkylator-based chemotherapy or high dose chemotherapy and autologous stem cell transplantation (SCT) will develop t-MDS/ AML within 10 years of primary therapy. 3 The evaluation of new therapies such as radioimmunotherapy 4 and fludarabine-based combination chemotherapy and chemoimmunotherapy regimens should include an assessment of the risk of t-MDS/AML.
Therapy-related myeloid neoplasms are a distinct entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues. 5 Cytotoxic agents associated with this complication include alkylating agents, topoisomerase II inhibitors, ionizing radiation, antimetabolites and antitubulin agents. 5, 6 The WHO classification considers t-MDS/AML as a unique clinical syndrome even though some cases may satisfy the morphological or cytogenetic criteria for other entities. Indeed, particular cytotoxic agents are associated with t-MDS/ AML with characteristic biological and clinical features. Alkylating agents and/or radiation tend to be associated with MDS/AML, with a gradual dysplastic clinical onset and a latency period of 5-10 years, with unbalanced chromosomal aberrations mainly involving chromosomes 5 and 7. 7 Topoisomerase II inhibitors have been associated with overt AML without a preceding myelodysplastic phase with a shorter latency period and balanced chromosome translocations frequently involving 11q23 (MLL) or 21q22 (RUNX1). 5 The prognosis of t-MDS/AML is generally poor, with a median survival o1 year. 7 Fludarabine is a purine analogue with marked efficacy in indolent lymphoproliferative disorders. 8, 9 As part of combination chemotherapy, fludarabine achieves high response rates in CLL and indolent lymphoma. [10] [11] [12] Fludarabine inhibits DNA repair and augments the cytotoxic effect of DNA damaging agents such as cyclophosphamide. 13 This enhancement of DNA damage may also affect marrow progenitor cells. Such a mechanism could explain the observed impairment of peripheral blood progenitor cell collection after prior fludarabine treatment and could predispose to an increased risk of t-MDS/AML. 14 The aim of this study was to investigate the incidence and characteristics of t-MDS/AML after treatment with fludarabine in combination with other cytotoxic agents for lymphoproliferative disorders and identify risk factors for its development. It updates our previously reported experience of 137 patients treated with fludarabine combination chemotherapy where 10 patients had developed t-MDS/AML (crude rate 7.3% at a median follow-up of 40 months). 15 
Materials and methods
Review of the Peter MacCallum Cancer Centre Pharmacy database from 1996 to 2008 identified 176 patients with indolent lymphoproliferative disorders treated with fludarabine combined with cyclophosphamide (C) and/or mitoxantrone (M) ± rituximab (R) as initial (57 patients) or salvage therapy (119 patients). Details of treatment protocols have been previously reported. 12, 16 All patients had at least 6 months follow-up since commencing treatment and were reviewed at Peter MacCallum Cancer Centre with clinical assessment and disease-appropriate investigations. Bone marrow examinations were performed to assess disease response or to investigate unexplained cytopenias or abnormal peripheral blood smears. Institutional board review and patient consent were not required, as this was a retrospective quality-assurance activity assessing complications of standard therapy at our institution.
Kaplan-Meier analysis was used to estimate time-to-t-MDS/ AML (TTMDS), defined as the time from first exposure to fludarabine combination therapy to onset of t-MDS/AML, censored at date of last follow-up or by death. The Mantel-Cox log-rank test was used to assess the effects of patient characteristics and other variables on TTMDS, including age, gender, disease type, treatment with anthracyclines, alkylating agents or radiation therapy at other times, treatment with high dose chemotherapy and autologous SCT, number of fludarabine containing treatment episodes, number of prior lines of cytotoxic treatment, and the type of fludarabine combination therapy (Table 1) . It was not possible to use a study close-out (censor) date in the analysis and so results should be treated with some degree of caution.
Results
In all, 176 patients treated with fludarabine combination were followed for a median of 41 months (range 6-125 months). Patients had at least 6 months follow-up from commencement of treatment and one third (56 patients) have now been followed for 45 years. In all, 112 patients (63.6%) were males, and the median age of all patients was 59 years (range 26-85 years) at the time they were first treated with fludarabine in combination with another cytotoxic agent. Underlying disease was CLL in 82 patients (46.6%), follicular lymphoma (FL) in 54 patients (30.7%), Waldenströ m macroglobulinemia or marginal zone lymphoma in 24 patients (13.6%) and mantle cell lymphoma in 16 patients (9.1%).
To date, 19 cases of t-MDS/AML (Table 2) have been identified for an overall crude rate of 10.8% (13 refractory cytopenia with multilineage dysplasia, 2 chronic myelomonocytic leukemia, 1 refractory anemia with excess blasts and 3 AML with multilineage dysplasia). The diagnosis was made at a median of 42 months (range 5-99 months) following the first treatment with fludarabine in combination with another cytotoxic agent. The estimated t-MDS/AML rates at 3 and 5 years were 5.6% (95% confidence interval ¼ 2.8-10.9%) and 10.5% (95% confidence interval ¼ 5.9-18.2%), respectively ( Figure 1a) . Median overall survival post-t-MDS/AML diagnosis was 11 months.
Patients developing t-MDS/AML included 11 with FL (crude rate 20.4%), 5 with CLL (6.1%), 3 with Waldenströ m macroglobulinemia or marginal zone lymphoma (12.5%) and no patients with mantle cell lymphoma (P ¼ 0.221). Most t-MDS/ AML patients had received additional treatments, but three with FL had fludarabine combination as their only treatment. There was a median number of 2 prior cytotoxic treatments (before the first fludarabine combinationFrange 0-6) and a median of 4 (range 0-7) cytotoxic treatments other than the first fludarabine combination prior to the development of t-MDS/AML. Excluding the first fludarabine combination, 15 of the 19 patients who developed t-MDS/AML had been treated with alkylators, 8 with anthracyclines and 6 with radiotherapy including one with radioimmunotherapy. Treatment with steroids, rituximab and interferon as single agents was not included in this assessment. The type and number of lines of other cytotoxic treatments were not statistically significant risk factors for the development of t-MDS/AML when total patient cohort was assessed, although prior cytotoxic therapy was associated with a trend toward increasing the risk of t-MDS/AML (P ¼ 0.067) (Figure 1b) . Fludarabine-associated myelodysplasia and AML DA Carney et al However, the type of fludarabine combination therapy was significantly associated with the risk of t-MDS/AML. Eleven patients (6.3%) received mitoxantrone (M) with their first fludarabine (F) (FM ± steroids in 3, fludarabine, cyclophosphamide and mitoxantrone (FCM) in 1 and FCMR in 7) combination treatment and four of those (36.4%) developed t-MDS/AML. Median TTMDS was significantly shorter for those patients treated with fludarabine with mitoxantrone (F þ M) (P ¼ 0.007), being 6.3 years compared with 410.1 years without mitoxantrone (Figure 1c) . The rate of t-MDS/AML at 5 years was 40.0% for F þ M compared with 7.8% without mitoxantrone.
The type of lymphoproliferative disease did not effect TTMDS when all four diseases were considered but when the two largest groups were compared, FL had a higher t-MDS/AML risk than CLL (P ¼ 0.05) (Figure 1d ). The increased risk in FL patients may have been influenced by the greater proportion of these patients with prior cytotoxic treatment (78% compared with 59%). Indeed, the CLL patients who developed t-MDS/AML had all received prior cytotoxic therapy. A higher proportion of patients with FL were treated at other times with anthracyclines (61%), alkylating agents (81%) and radiotherapy (48%) compared with those with CLL (24, 67 and 32%, respectively) although overall, these other treatments did not feature as statistically significant risk factors for t-MDS/AML.
Karyotypic analysis of t-MDS/AML was typically complex (Table 2) . Results are available in 16 of the 17 cases assessed. Thirteen of the 16 had cytogenetic aberrations. Abnormalities of chromosome 7 were observed in 7 patients, chromosome 13 was involved in 7 patients and chromosome 5 in 5 patients.
Autologous SCT was used as treatment for t-MDS/AML in three patients. Durable responses were not achieved in these patients (survival 5, 5 and 8 months post-autologous SCT). Allogeneic SCT was performed in three patients with t-MDS/ AML. One patient died from early transplantation-related complications and the other two patients are alive at 4 and 5 months post-allogeneic SCT.
Discussion
There is growing recognition of the leukemogenic potential of purine analogue therapy, particularly when combined with other DNA damaging agents. 17 Assessment of the risk of this complication is often confounded in patients with indolent lymphoproliferative disorders by the frequent exposure to multiple lines of cytotoxic therapy. Rates of t-MDS/AML will also vary with the length of follow-up. Our median follow-up of 41 months is still relatively early in view of the median time of 42 months to the development of t-MDS/AML. Furthermore, our overall crude rate of 10.8% is also likely to be an underestimate because bone marrow examinations were only performed in patients with either cytopenias or marked morphologic dysplastic changes in the peripheral blood. Conversely, estimations may be falsely high if early reversible dysplastic features and cytopenias associated with cytotoxic treatment are misinterpreted. 18 In our study, the diagnosis of t-MDS/AML was not made within 6 months of cytotoxic treatment unless the diagnostic features were confirmed at a later time or a clonal cytogenetic abnormality was detected. An abnormal karyotype occurs in the leukemic cells in over 90% of t-MDS/AML cases and therefore the diagnosis should be made with caution in the absence of this feature. 5 Other published trials of fludarabine combination therapies allow a comparison to be made with the rates of t-MDS/AML we have observed. In the CALGB 9011 study of frontline CLL treatment, the rate of t-MDS/AML was 3.5% for the combination of fludarabine and chlorambucil compared with 0.5 and 0% for patients randomized to receive fludarabine or chlorambucil alone. 19 More recently, fludarabine in combination with cyclophosphamide and rituximab has demonstrated remarkable activity in CLL. 2 Evaluation of 300 patients receiving this regimen as initial therapy, with a median follow-up of 6 years, revealed eight patients who developed MDS for an actuarial risk of 2.8% at 6 years. With a median follow-up of 42 months, fludarabine in combination with mitoxantrone and dexamethasone has been associated with a similar rate of MDS (4%) as initial therapy of indolent non-Hodgkin lymphoma. 20 Another trial assessing FCM as initial treatment in 120 patients with advanced FL reported no late toxicity after a median follow-up of 3.9 years. 21 In our study, there was a high rate of t-MDS/AML in patients who received mitoxantrone as part of their first fludarabine combination treatment. This was the most highly significant risk factor for t-MDS/AML identified in our cohort of patients. In contrast to the fludarabine, mitoxantrone and dexamethasone and FCM studies cited above, all patients in our series had prior cytotoxic treatment. Mitoxantrone dose may also play a role in the risk of t-MDS/AML with our patients generally receiving [8] [9] [10] In this study, t-MDS/AML developed in eight patients (crude incidence 20%) and all had received prior alkylator therapy and fludarabine in combination with cyclophosphamide. The risk of MDS was also associated with the total dose of fludarabine. Fludarabine may also play a role in the development of t-MDS/AML following subsequent cytotoxic therapy. In a review of 746 patients treated with yttrium-90 ( 90 Y) ibritumomab tiuxetan (radioimmunotherapy) 19 patients (2.5%) developed t-MDS/AML at a median of 4.4 years follow-up. 4 FL histology and prior purine analogue therapy were the only significant risk factors identified for the development of t-MDS/AML.
In our study, the effect of both previous and subsequent cytotoxic treatment in relation to the initial fludarabine combination therapy were assessed. Treatment at other times with alkylators, anthrayclines, autologous SCT and radiotherapy did not significantly influence TTMDS although there was a trend toward prior cytotoxic therapy increasing the risk of t-MDS/AML (P ¼ 0.067). However, the development of t-MDS/ AML in three patients following fludarabine combination therapy as their only line of treatment has demonstrated a risk independent of other cytotoxic therapy. These three patients comprise 7% of 43 patients who had no other cytotoxic therapy. Overall, gender did not reach statistical significance (P ¼ 0.115), but notably the three patients who developed t-MDS/AML following fludarabine combination therapy as their only line of treatment were all females with FL.
Fludarabine is able to target quiescent as well as cycling cells. 23 This property contributes to its efficacy in the treatment of indolent lymphoproliferative disorders but may also produce hematopoietic stem cell toxicity. This is evident in the prolonged cytopenias and impaired ability to harvest stem cells associated with fludarabine-based regimens, 2, 18, 24 and may also be manifest by t-MDS/AML. The t-MDS/AML associated with fludarabine combination therapy has similar cytogenetic abnormalities to those seen with alkylating agents. 19, 20 This may reflect the role of fludarabine in preventing repair of DNA damage initiated by the other cytotoxic agent. However, it is interesting to note the presence of chromosome 7 abnormalities in case reports of t-MDS/AML associated with single agent fludarabine, suggesting that it may also exert a direct mutagenic effect. 25, 26 Our results also show an association of fludarabine with chromosome 7 abnormalities although chromosome 13 and 5 abnormalities were also prominent. Three of the four cases of t-MDS/AML associated with F þ M had cytogenetic assessments and all demonstrated deletions of chromosome 7 in addition to multiple other aberrations.
Fludarabine may also cause undetected genetic damage or deplete lymphocytes involved in immunosurveillance of malignant cells. This may play a role in the increased risk of non-hematopoietic malignancies reported after fludarabine treatment. 27 Our results confirm the poor prognosis of t-MDS/AML and highlight the importance of prevention through identification of risk factors prior to fludarabine combination therapy. The susceptibility of some patients could result from defects in drug metabolism or DNA repair and these factors should be assessed in the future. Early detection of MDS in patients at risk is also worthwhile as more effective interventions, particularly azacitidine, are becoming available. 28 
Conclusion
Fludarabine combination chemotherapy is associated with a moderate risk of t-MDS/AML. Our results suggest that fludarabine combined with mitoxantrone as salvage therapy has a greater risk of t-MDS/AML and if this observation is confirmed in other series, such combinations should be used with caution outside the setting of a clinical trial. Fludarabine combination regimens are highly effective in lymphoproliferative disorders but further research is required to identify those patients at a higher risk for the development of t-MDS/AML to enable more selective application of this therapy.
